AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gómez, C. M. H.
Right arrow Articles by Palazzo, M. G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gómez, C. M. H.
Right arrow Articles by Palazzo, M. G. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1798-1802, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients

C. M. H. Gómez,* J. J. Cordingly,dagger and M. G. A. Palazzo

Department of Intensive Care and Anaesthesia, Charing Cross Hospital, London W6 8RF, United Kingdom

Received 3 April 1998/Returned for modification 3 November 1998/Accepted 5 May 1999

Many critically ill patients have increased extracellular fluid which might affect ceftazidime pharmacokinetics. We investigated the pharmacokinetics of ceftazidime in 15 adult intensive care patients receiving 2 g of ceftazidime intravenously three times a day. The ceftazidime mean (standard deviation) apparent volume of distribution and terminal-phase half-life were 56.91 (25.93) liters and 4.75 (1.85) h, respectively, significantly greater than values reported previously for healthy controls (P < 0.001). The mean ceftazidime clearance and area under the curve at steady state were not significantly different from those previously reported for controls. We conclude that ceftazidime pharmacokinetics in critically ill patients were altered by an increased volume of drug distribution and elevated elimination half-life.


* Corresponding author. Mailing address: Department of Intensive Care and Anaesthesia, Charing Cross Hospital, Fulham Palace Rd., London W6 8RF United Kingdom. Phone: 44 181 846 7920 or 44 181 846 7017. Fax: 44 181 846 7585. E-mail: c.gomez{at}ic.ac.uk.

dagger Present address: Department of Anaesthesia and Intensive Care, Hammersmith Hospital, London W12 OHS, United Kingdom.


Antimicrobial Agents and Chemotherapy, July 1999, p. 1798-1802, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.